Corrigendum to “Inosine: A broad-spectrum anti-inflammatory against SARS-CoV-2 infection-induced acute lung injury via suppressing TBK1 phosphorylation” [J. Pharm. Anal. 13 (2023) 11–23]

doi: 10.1016/j.jpha.2025.101517

• Ningning Wang^a,b , 
• Entao Li^c , 
• Huifang Deng^a , 
• Lanxin Yue^a , 
• Lei Zhou^a , 
• Rina Su^c,d , 
• Baokun He^e , 
• Chengcai Lai^a , 
• Gaofu Li^a , 
• Yuwei Gao^{c ,}  , 
• Wei Zhou^{a ,}  , 
• Yue Gao^{a,b ,} 

• a. Department of Pharmaceutical Sciences, Beijing Institute of Radiation Medicine, Beijing, 100850, China;

• b. Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China;

• c. Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun, 130122, China;

• d. College of Veterinary Medicine, Jilin Agricultural University, Changchun, 130022, China;

• e. Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China